可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Cleland JGF,McGowan J,Clark A.The evidence for β-blockers in heart failure[J]. BMJ,1999,318:824-825.
[2]Exner DV,Reiffel JA,Epstein AE,et al.Beta-blocker use and survial in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators(AVID) trail[J]. J Am Coll Cardiol,1999,34:325-333.
[3]Waldoa AL,Cammb AJ,deRuyterc H,et al.Effect of d-sotalol on mortality in patient swith left ventricular dysfunction after recent and remote myocardial infarction[J]. Lancet,1996,348:7-12.
[4]Doval C,Nul DR,Grancelli HO,et al.Randomised trail of low-dose amiodar one in severe congestive heart failure[J]. Lancet, 1994, 44:493-498.
[5]Singh SN,Fletcher RD,Fisher SG,et al.Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trail of antiarrhythmic therapy in congestive heart failure[J].N Engl J Med,1995,33:77-82.
[6]Julian DG,Camm AJ,FranginG,et al.Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators[J].Lancet,1997,49:667-674.
[7]Cairns JA,Connolly SJ,Roberts R,et al.Randomised trial of outcome after myocardial infarction in patients with frequentor repetitive ventricular premature depolarisations: CAMIAT.Canadiana miodarone myocardial infarction arrhyth miatrial investigators[J].Lancet,1997,49:675-682.
[8]Farre J,Romero J,Rubio JM,et al.Amiodarone and primary prevention of sudden death: critical review of adecade of
clinicaltrials[J]. Am J Cardiol,1999,83:55D-63D.
[9]Kuck KH,Cappato R,Siebels J,et al.Randomized comparison of antiarrhythmic drug therapy with implantable cardioverter defibrillators in patients resuscitated from cardiacar rest:the Cardiac Arrest Study Hamburg(CASH)[J]. Circulation,2000,102:748-754.
[10]The antiarrhythmics versus implantable defibrillators(AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias[J].N Engl J Med,1997,337:1576-1583.
[11]Mitchell LB,Pineda EA,Titus JL,et al.Sudden death in patients with implantable cardioventer defibrillators[J].J Am Coll Cardiol,2002,39:1323-1328.
[12]Connolly SJ,Gent M,Roberts RS,et al.Canadia nimplantable defibrillator study (CIDS): a randomized trial of the implantable cardioverterde fibrillator against amiodarone[J].Circulation,2000,101:1297-1302.
[13]Moss AJ,Hall WJ,Cannom DS,et al.Improved survival with animplanted defibrillator in patients with coronary diseaseat high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators[J].N Engl J Med,1996,335:1933-1940.
[14]Buxton AE,Lee KL,Fisher JD,et al.Arandomized study ofthe prevention ofsudden cardiac death in patients with coronaryartery disease[J].N Engl J Med,1999,341:1882-1890.
[15]Moss AJ,Zareba W,Hall WJ,et al.Prophylactic implantation of adefibrillator in patients with myocardial infarction and reduced ejection fraction[J].N Engl J Med,2002,46:877-883.
[16]Bigger JT.Prophylacticuse of implanted cardiacde fibrillators in patients at high risk forvent ricular arrhythmias after coronary-artery bypass graft surgery.Coronary artery bypass graft (CABG) patchtrial investigators[J].N Engl J Med,1997,337:1569-1575.
[17]Parkes J, BryantJ, Milne R. Implantable cardioverter efibrillators in arrhythmias: arapid and system aticre view of effectiveness[J].Heart,2002,87:438-442.